Tong Hua Dong Bao Insulin To Compete With Novo Nordisk, Eli Lilly
This article was originally published in PharmAsia News
Executive Summary
Tong Hua Dong Bao Pharmaceutical projected its 2009 output of recombinant human insulin at 3,000 Kg and aims to compete with Novo Nordisk and Eli Lilly domestically and internationally. Tong Hua Dong Bao invested RMB 600 million in facility expansions, and with the increased output it expects to boost its market share in China 50 percent. In addition, relevant national agencies have tested the quality of Tong Hua Dong Bao's insulin and reported it to be similar to that of Novo Nordisk and Eli Lilly. Tong Hua Dong Bao's product is also at least 30 percent cheaper giving the Chinese company a competitive advantage in the international market. Tong Hua Dong Bao has started targeting affluent oil-producing countries in the Middle East as potential customers. (Click here for more
You may also be interested in...
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.